CASI Phase 1/2 Clinical Trial: First Patient Dosed with CID-103 for Immune …
CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing innovative therapeutic products, has marked a significant milestone by dosing the first patient in its Phase 1/2 clinical trial of CID-103 for chronic Immune Thrombocytopenia (ITP) in China. The study aims to evaluate the safety and tolerability of CID-103 in adult patients with ITP, a condition that currently has limited treatment options available.
Dr. Wei-Wu He, Chairman and CEO of CASI, expressed his excitement about this development, highlighting the importance of this trial for both the CID-103 program and patients with chronic ITP. The company’s commitment to accelerating clinical development is evident in the rapid execution of this trial, which is designed to provide essential safety and dose-response data. This data will play a crucial role in guiding the future development of CID-103 for additional autoimmune indications with significant unmet medical needs.
CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that targets a unique epitope. In preclinical studies, CID-103 has demonstrated promising efficacy and safety compared to other anti-CD38 monoclonal antibodies.
CASI Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapeutics and pharmaceutical products globally, with a particular emphasis on hematology oncology, organ transplant rejection, and autoimmune diseases. The company plans to lead the market by launching medicines in the Greater China region, leveraging its regulatory and commercial expertise in China and its global drug development capabilities. CASI operates in China through its subsidiary, CASI Pharmaceuticals (China) Co., Ltd., based in Beijing.
This announcement contains forward-looking statements under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company’s strategic and operational plans, as well as statements from management, contain forward-looking statements. These statements involve inherent risks and uncertainties, and factors such as regulatory developments in China, market volatility, and clinical trial outcomes could impact actual results. The company remains focused on advancing its pipeline of therapeutic products and addressing unmet medical needs.
